Vitamin E study
This article was originally published in The Tan Sheet
Executive Summary
Vitamin E along with use of Hoechst-Roussel's ACE inhibitor Altace (ramipril) will be investigated in the prevention of heart attacks, strokes, peripheral vascular disease and death in high risk patients under a four-year, 9,000-patient trial set to begin July 1. The $11 mil. Heart Outcomes Prevention Evaluation (HOPE) trial is being funded by the Medical Research Council of Canada, Hoechst-Roussel and Upjohn, which comarkets Altace in the U.S. Eastman Chemical, Henkel Fine Chemicals and Eisai USA will provide the vitamin E for the trial. HOPE includes 228 sites in the U.S., Canada, Europe and South America